Topics

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

05:00 EDT 29 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available New collaboration aims to develop novel peptide poly-agonists for the ...

Other Sources for this Article

Contact:
Gubra
Henrik Blou
CEO
Phone: +45 2861 6845
hbl@gubra.dk

Contact:
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Phone: +49 (6132) 77-90815
reinhard.malin@boehringer-ingelheim.com

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists"

Quick Search

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...